Phase 4 N=19 Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome
Anticholinergics Toxicity
Primary: Comparison of RASS Score Between Physostigmine and Lorazepam: Before Bolus — 1.5; 1 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=59 The Effect of Anticholinergics on Cognitive Function in the Elderly
Mental Competency · Urinary Bladder, Overactive · Cognitive Function
Primary: Hopkins Verbal Learning Test - Revised — 22.00; 24.38; 6.71; 7.83 units on a scale
N/A N=244,976 Anticholinergic Risk Scale and Resource Use After Elective Noncardiac Surgery
Length of Stay · Anti Cholinergics · Surgical Procedure, Operative
Primary: Hospital Length of Stay — 6.8; 7.8; 7.5 Days
Phase 2 N=10 Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI
Hypotension, Postural
Primary: Systolic Blood Pressure — 97; 103; 90; 88 mm Hg
Phase 4 N=20 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
Overactive Bladder
Primary: Cerebral Spinal Fluid Levels of Sanctura XR® at Day 10 Post-dose — NA Nanograms (ng) per milliliter (mL)
Phase 4 N=12 Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
Elderly · Pharmacokinetics · Overactive Bladder
Primary: Cerebral Spinal Fluid Levels of Trospium at Day 10, Hour 5 — NA Picograms per milliliter (pg/mL)
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 4 N=5 Mirabegron in Parkinson Disease and Impaired Cognition
Parkinson Disease · Overactive Bladder · Impaired Cognition
Primary: Change in Montreal Cognitive Assessment Total Score — 1.5; 2 units on a scale
Phase 2 N=58 A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
Hyperhidrosis
Primary: Posterior Probability That the Response Rate is Greater Than 50% — 1; 0.9997 Posterior Probability
Phase 1 N=27 Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
Memory Impairment · Alzheimer's Disease
Primary: Change From Baseline in the Verbal Recall Memory (VRM) Total Number of Correct Responses for Delayed Recall at 1 Hour After Scopolamine Administration — -6.7; -7.0…
Phase 2 N=105 Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 10; 10; 9; 10 Participants
Phase 4 N=26 A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
Cognition
Primary: Change From Baseline in Cognitive Function Composite Score - Power of Attention — 1413.67; 1423.38; 1401.21; -5.86 msec — p=0.3771
N/A N=52 Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation
Sialorrhea
Primary: Difference in Salivary Flow Rate (ml/Min) Between Study Groups — .072; .003; NA ml/min
Phase 3 N=62 Comparision of Different Dose of Neostigmine at Advanced Decurarization
Anesthesia
Primary: Mesure of the Train-of-four (TOF) — 3.8; 4.5; 11.5; 19 minute
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
N/A N=23 Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease
Parkinson's Disease
Primary: Fall Frequency Per Day — 0.13; 0.25 Number Falls/Day — p=0.049
Phase 4 N=22 Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults
Mental Health · Geriatrics
Primary: Psychomotor Vigilance Test (PVT) — 302.62; 277.13 milliseconds
Phase 2 N=22 Atomoxetine and Oxybutynin in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 28.5; 7.5 events/hours of sleep — p=<0.001
Phase 2 N=49 Effects of Cholinergic Augmentation on Measures of Balance and Gait
Parkinson's Disease
Primary: Delta Medio-lateral Postural Sway Range (Foam) — 0.007; -0.004 m/s^2
Phase 2 N=62 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
Phase 2 N=80 Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension
Acute Pancreatitis · Intra-abdominal Hypertension
Primary: Percent Change of IAP After Treatment — -18.7; -5.4; -27.2; -20.0 percent change of IAP
Phase 2 N=30 Use of Pyridostigmine for Constipation in Diabetics
Constipation · Diabetes Mellitus · Colonic Transit
Primary: Colonic Geometric Center at 24 Hours (GC24) Measured by Scintigraphy — 1.96; 1.98; 2.45; 1.84 units on a scale — p=<0.01
Phase 3 N=111 Cocaine/Crack and Reduction of Compulsion With Biperiden
Cocaine Dependence
Primary: Compulsion — 5.9; 5.5 score on a scale — p=<0.05
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
N/A N=10 Phamacological Reversal of Airway Instability During Sedation
Upper Airway Obstruction
Primary: AHI - Apnea Hypopnea Index — 14.5; 27.9; 11.3; 12.1 events per hour